GO:0086100 endothelin receptor signaling pathway: Vasoactivity, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0086100 describes the G protein-coupled receptor signaling pathway initiated by endothelin binding to endothelin receptors on the cell surface.
• The pathway is mediated by two main receptor subtypes, EDNRA and EDNRB, which couple to Gq/11, Gs, and Gi proteins to regulate calcium, cAMP, and downstream transcription.
• Endothelin-1 (EDN1) is the principal ligand and a potent vasoconstrictor, with additional roles in cell proliferation, survival, and differentiation.
• Dysregulated endothelin receptor signaling is implicated in pulmonary arterial hypertension, cancer, cardiovascular disease, and fibrosis.
• Structural studies of endothelin receptors have revealed distinct binding pockets and conformational changes that guide pharmacological targeting.
• CRISPR-based knockout, knock-in, and overexpression models are essential for dissecting receptor-specific functions and validating drug targets in this pathway.
Description
The endothelin receptor signaling pathway (GO:0086100) is a biological process in which endothelin peptides bind to their cell-surface receptors, triggering intracellular signals that regulate diverse cellular responses, including contraction, proliferation, and gene expression. This pathway is a canonical example of G protein-coupled receptor (GPCR) signaling and is critical for vascular homeostasis and development. Endothelins are among the most potent vasoconstrictors known, and their receptors are expressed in numerous tissues, making this pathway a central node in physiology and disease. Researchers study GO:0086100 to understand how endothelin signals are transduced, how they are dysregulated in conditions such as pulmonary arterial hypertension and cancer, and how they can be targeted therapeutically. The pathway's complexity, involving multiple ligands, receptor subtypes, and G protein couplings, necessitates precise experimental models and advanced molecular tools.
endothelin receptor signaling pathway At A Glance
| GO ID | GO:0086100 |
|---|---|
| GO term | endothelin receptor signaling pathway |
| Ontology | biological_process |
| Synonym | endothelin signaling pathway |
| Definition | A G protein-coupled receptor signaling pathway initiated by endothelin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| Major function | Transduces endothelin signals to regulate vasoconstriction, cell proliferation, survival, and gene expression. |
| Key receptors | EDNRA (ETA) and EDNRB (ETB). |
| Key ligands | EDN1, EDN2, EDN3. |
| G proteins involved | Gq/11, Gs, Gi, and others. |
What Is GO:0086100?
According to the Gene Ontology, GO:0086100 (endothelin receptor signaling pathway) is defined as a G protein-coupled receptor signaling pathway initiated by endothelin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. In simpler terms, it is the entire sequence of molecular events from the moment an endothelin molecule docks onto its receptor until the cell responds by changing its behavior or gene expression.
Why Is endothelin receptor signaling pathway Important in Cell Biology?
The endothelin receptor signaling pathway is essential for cardiovascular homeostasis, and its dysregulation contributes to a wide range of human diseases, including pulmonary arterial hypertension, systemic hypertension, cancer, and fibrosis. Understanding this pathway at the molecular level enables the development of targeted therapies, such as endothelin receptor antagonists, and provides insights into GPCR biology more broadly.
• Regulates vascular tone and blood pressure through potent vasoconstriction.
• Controls cell proliferation, survival, and apoptosis in various tissues.
• Implicated in the pathogenesis of pulmonary arterial hypertension.
• Plays a role in cancer progression, angiogenesis, and metastasis.
• Involved in cardiac development and function.
• Mediates fibrosis in kidney, lung, and liver.
• Serves as a target for drugs like bosentan and ambrisentan.
• Provides a model for understanding GPCR signaling bias and regulation.
• Contributes to pain signaling and neuroregulation.
• Offers opportunities for CRISPR-based therapeutic target validation.
What Happens During endothelin receptor signaling pathway?
Ligand Binding and Receptor Activation
In simple terms: An endothelin molecule attaches to its receptor on the cell surface, switching the receptor on.
Endothelin-1 (EDN1), the predominant isoform, binds with high affinity to EDNRA and EDNRB, two GPCRs. Structural studies have revealed that endothelin peptides adopt a bicyclic conformation that inserts into a deep binding pocket of the receptor, inducing conformational changes that activate the receptor. Ligand binding is the first step in the pathway and determines receptor selectivity and downstream signaling.
G Protein Coupling and Second Messenger Generation
In simple terms: The activated receptor turns on G proteins, which then produce small messenger molecules inside the cell.
Activated EDNRA and EDNRB couple primarily to Gq/11, leading to activation of phospholipase C (PLC), which hydrolyzes PIP2 into IP3 and DAG. IP3 triggers calcium release from intracellular stores, while DAG activates protein kinase C (PKC). EDNRB can also couple to Gi and Gs, inhibiting or stimulating adenylyl cyclase and modulating cAMP levels. This coupling diversity allows the pathway to fine-tune cellular responses.
Downstream Signaling Cascades
In simple terms: The messengers activate a chain of proteins that carry the signal to the nucleus and other parts of the cell.
Elevated calcium and PKC activity activate multiple downstream effectors, including mitogen-activated protein kinases (MAPKs), Rho kinase, and phosphatidylinositol 3-kinase (PI3K)/Akt. These cascades regulate cytoskeletal rearrangements, cell contraction, proliferation, and survival. Additionally, receptor tyrosine kinases such as EGFR can be transactivated, further diversifying the signal.
Regulation of Transcription and Cellular Responses
In simple terms: The signal reaches the nucleus and changes which genes are turned on or off, leading to long-term cellular changes.
Activated MAPKs and other kinases translocate to the nucleus and phosphorylate transcription factors such as AP-1, NF-κB, and CREB, altering gene expression programs. This transcriptional regulation underlies long-term effects of endothelin signaling, including cell growth, differentiation, and production of extracellular matrix components. The pathway thus ends with changes in cellular behavior and gene expression, as defined by GO:0086100.
Receptor Desensitization and Internalization
In simple terms: After signaling, the receptor is turned off and pulled inside the cell to stop the response.
Following activation, endothelin receptors are phosphorylated by G protein-coupled receptor kinases (GRKs) and bind β-arrestins, leading to desensitization and internalization. This negative feedback prevents excessive signaling and is crucial for maintaining vascular homeostasis. Dysregulation of these processes can contribute to disease.
Key Genes Involved in GO:0086100 endothelin receptor signaling pathway
The following genes encode the core components of the endothelin receptor signaling pathway, including ligands, receptors, and key downstream effectors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EDN1 | Encodes endothelin-1, the primary ligand for EDNRA and EDNRB | Central to vasoconstriction and cardiovascular disease models |
| EDN2 | Encodes endothelin-2, a ligand with roles in development and reproduction | Less studied but implicated in ovarian and intestinal functions |
| EDN3 | Encodes endothelin-3, a ligand for EDNRB | Critical for neural crest development and Hirschsprung disease |
| EDNRA | Encodes ETA receptor, mediates vasoconstriction and cell proliferation | Major drug target in pulmonary arterial hypertension and cancer |
| EDNRB | Encodes ETB receptor, mediates vasodilation and clearance of endothelin | Involved in development and melanoma |
| GNAQ | Encodes Gq alpha subunit, couples EDNRA/EDNRB to PLC | Key mediator of calcium signaling |
| GNA11 | Encodes G11 alpha subunit, alternative Gq family member | Compensatory roles in GPCR signaling |
| PLCB1 | Encodes phospholipase C beta 1, generates IP3 and DAG | Essential for downstream calcium release |
| PRKCA | Encodes protein kinase C alpha, activated by DAG | Regulates many downstream targets |
| MAPK1 | Encodes ERK2, a MAP kinase involved in proliferation | Common readout of pathway activation |
| MAPK3 | Encodes ERK1, partner of ERK2 | Used in phospho-ERK assays |
| AKT1 | Encodes Akt1, a survival kinase activated by PI3K | Linked to cell survival and growth |
| RHOA | Encodes RhoA, a small GTPase regulating cytoskeleton | Mediates calcium sensitization in smooth muscle |
| ARRB1 | Encodes beta-arrestin-1, involved in receptor desensitization | Regulates receptor internalization |
| ARRB2 | Encodes beta-arrestin-2, similar to ARRB1 | Modulates signaling bias |
| GRK2 | Encodes G protein-coupled receptor kinase 2, phosphorylates receptors | Key negative regulator |
| EGFR | Encodes epidermal growth factor receptor, transactivated by endothelin | Contributes to mitogenic signaling |
How Is endothelin receptor signaling pathway Regulated?
Endothelin receptor signaling is tightly regulated at multiple levels. Receptor desensitization and internalization are controlled by GRK-mediated phosphorylation and β-arrestin recruitment. Negative feedback loops involving protein kinase C and calcium/calmodulin-dependent kinases modulate receptor sensitivity. Additionally, endothelin-converting enzymes (ECE1, ECE2) regulate ligand availability, and receptor expression levels are influenced by transcription factors and epigenetic mechanisms. Dysregulation of these control mechanisms can lead to pathological signaling in diseases such as hypertension and cancer.
endothelin receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EDN1 | Pulmonary arterial hypertension, hypertension | EDN1 knockout or overexpression in endothelial cells |
| EDNRA | Cancer, cardiovascular disease | EDNRA knockout in cancer cell lines or mouse models |
| EDNRB | Hirschsprung disease, melanoma | EDNRB point mutations in neural crest cells |
| ECE1 | Hypertension, fibrosis | ECE1 knockout mice or cell lines |
| GNAQ | Uveal melanoma, vascular disorders | GNAQ knock-in of activating mutations |
Pulmonary Arterial Hypertension (PAH)
Endothelin-1 and its receptors are critically involved in the pathogenesis of PAH, where excessive vasoconstriction and vascular remodeling lead to increased pulmonary artery pressure. Endothelin receptor antagonists such as bosentan and ambrisentan are approved for PAH treatment, highlighting the clinical importance of this pathway.
Cancer
Endothelin receptor signaling promotes tumor cell proliferation, survival, angiogenesis, and metastasis in various cancers, including prostate, ovarian, and melanoma. EDNRB acts as a tumor suppressor in some contexts, while EDNRA often promotes tumor progression. Targeting this pathway is an active area of oncology research.
Cardiovascular and Fibrotic Diseases
Dysregulated endothelin signaling contributes to systemic hypertension, heart failure, and fibrosis in kidney, lung, and liver. Endothelin receptor antagonists are used in some cardiovascular conditions, and preclinical models are used to study their efficacy.
Developmental Disorders
Mutations in EDN3 or EDNRB cause Hirschsprung disease, a congenital disorder characterized by absence of enteric ganglia, due to defective neural crest cell migration. This highlights the role of endothelin signaling in development.
From endothelin receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does EDNRA mediate vasoconstriction in vivo? | EDNRA knockout mouse or CRISPR knockout in vascular smooth muscle cells |
| What is the effect of EDNRB loss in development? | EDNRB knockout zebrafish or mouse, or knock-in of patient mutations |
| How does a specific EDNRA point mutation affect ligand binding? | CRISPR point-mutation knock-in in cell lines, followed by binding assays |
| Can we visualize EDNRA trafficking? | Tagged knock-in of EDNRA with fluorescent protein in cells |
| Does overexpression of EDN1 drive fibrosis? | Inducible EDN1 overexpression in fibroblasts or mouse models |
| Which genes are regulated by endothelin signaling? | CRISPR knockout of EDNRA/EDNRB followed by RNA-seq |
How to Study the endothelin receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Calcium imaging | Intracellular calcium release | Receptor activation by endothelin |
| cAMP assay | Cyclic AMP levels | Gi/Gs coupling |
| Western blot | Phosphorylation of ERK, Akt, PKC | Downstream pathway activation |
| RNA-seq | Global gene expression changes | Transcriptional regulation |
| Radioligand binding | Ligand-receptor affinity | Receptor pharmacology |
| Cryo-EM | Receptor structure and conformational changes | Drug design and mechanism |
| Immunofluorescence | Receptor localization and internalization | Trafficking studies |
| CRISPR screening | Gene essentiality and pathway modifiers | Target discovery |
Calcium Imaging and Second Messenger Assays
Calcium flux assays using fluorescent dyes (e.g., Fluo-4) are widely used to measure endothelin receptor activation in real time. cAMP assays can detect Gi/Gs coupling. These methods are essential for functional characterization of receptor variants and drug screening.
Phospho-Protein and Kinase Activity Assays
Western blotting for phosphorylated ERK, Akt, and PKC substrates provides readouts of downstream pathway activation. These assays are used to evaluate the impact of CRISPR-mediated gene edits on signaling.
Transcriptomics and RNA-seq
RNA sequencing after pathway stimulation or receptor knockout reveals global transcriptional changes driven by endothelin signaling. This approach identifies novel target genes and regulatory networks.
Receptor Binding and Structural Studies
Radioligand binding assays and cryo-EM structures of endothelin receptors provide insights into ligand-receptor interactions and drug design. These methods are critical for understanding receptor subtype selectivity.
How CRISPR Can Be Used to Study GO:0086100 endothelin receptor signaling pathway
Knockout
CRISPR knockout of EDNRA, EDNRB, or downstream effectors (e.g., GNAQ) in cell lines or primary cells allows researchers to determine their specific roles in endothelin signaling. Knockout models are used to validate drug targets and assess pathway redundancy.
Point Mutation
Introducing disease-associated point mutations (e.g., in EDNRB for Hirschsprung disease) via CRISPR base editing or homology-directed repair enables functional studies of receptor variants. These models help link genotype to signaling phenotype.
Knock-in
Knock-in of tagged receptors (e.g., GFP-EDNRA) or reporter genes (e.g., luciferase under an endothelin-responsive promoter) allows real-time tracking of receptor localization and transcriptional activity. This is valuable for high-content imaging and drug screening.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of EDN1, EDNRA, or EDNRB can model pathological overactivation of the pathway, as seen in cancer and fibrosis. Overexpression models are used to test inhibitors and study downstream effects.
How EDITGENE Supports endothelin receptor signaling pathway Research
Researchers studying endothelin receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway regulation, disease progression, or drug response. Precise genetic models are essential to move from correlation to causation.
Contact EDITGENE today to design your custom CRISPR model for endothelin receptor signaling pathway research.
Frequently Asked Questions About endothelin receptor signaling pathway
What is the endothelin receptor signaling pathway?
It is a G protein-coupled receptor signaling pathway initiated by endothelin binding to its receptor, leading to regulation of downstream cellular processes such as transcription (GO:0086100).
What genes are involved in endothelin receptor signaling?
Key genes include EDN1, EDN2, EDN3 (ligands), EDNRA and EDNRB (receptors), and downstream effectors like GNAQ, PLCB1, and MAPK1.
What are the main receptors for endothelin?
The two main receptors are EDNRA (ETA) and EDNRB (ETB), which are GPCRs with distinct tissue distributions and functions.
How does endothelin-1 signal inside the cell?
EDN1 binding activates Gq/11, leading to phospholipase C activation, IP3-mediated calcium release, and PKC activation, which then trigger MAPK and other cascades.
What diseases are associated with endothelin receptor signaling?
Dysregulation is linked to pulmonary arterial hypertension, cancer, cardiovascular disease, fibrosis, and Hirschsprung disease.
What drugs target endothelin receptors?
Endothelin receptor antagonists such as bosentan and ambrisentan are used to treat pulmonary arterial hypertension.
How can CRISPR be used to study endothelin signaling?
CRISPR knockout, knock-in, and overexpression models allow researchers to dissect gene function, model mutations, and validate drug targets in this pathway.
What is the role of EDNRB in development?
EDNRB is critical for neural crest cell migration; mutations cause Hirschsprung disease.
How is endothelin receptor signaling regulated?
It is regulated by receptor desensitization via GRKs and β-arrestins, and by negative feedback from downstream kinases.
What methods are used to study endothelin signaling?
Common methods include calcium imaging, cAMP assays, Western blotting for phospho-ERK, RNA-seq, and structural studies like cryo-EM.
Conclusion
The endothelin receptor signaling pathway (GO:0086100) is a fundamental GPCR pathway with broad physiological and pathological roles. Its dysregulation contributes to major human diseases, making it a prime target for therapeutic intervention. Continued research using advanced CRISPR models and multi-omics approaches will further elucidate its mechanisms and enable the development of more precise therapies.
References
- 1. Speck D et al.. 2022. Angiotensin and Endothelin Receptor Structures With Implications for Signaling Regulation and Pharmacological Targeting.. Front Endocrinol (Lausanne) 13:880002 PMID: 35518926
- 2. Davenport AP et al.. 2006. Endothelin.. Handb Exp Pharmacol PMID: 16999223
- 3. Houde M et al.. 2016. Endothelin-1: Biosynthesis, Signaling and Vasoreactivity.. Adv Pharmacol 77:143-75 PMID: 27451097
- 4. Shihoya W et al.. 2023. Structural insights into endothelin receptor signalling.. J Biochem 174(4):317-325 PMID: 37491722
- 5. Horinouchi T et al.. 2013. Endothelin receptor signaling: new insight into its regulatory mechanisms.. J Pharmacol Sci 123(2):85-101 PMID: 24077109
- 6. Bhalla A et al.. 2009. Endothelin receptor antagonism and cancer.. Eur J Clin Invest 39 Suppl 2:74-7 PMID: 19335749
- 7. Sandoval YH et al.. 2014. Endothelin-1 signaling in vascular physiology and pathophysiology.. Curr Vasc Pharmacol 12(2):202-14 PMID: 24568156
- 8. Sokolovsky M. 1995. Endothelin receptor subtypes and their role in transmembrane signaling mechanisms.. Pharmacol Ther 68(3):435-71 PMID: 8788566
